nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—RET—Signaling events regulated by Ret tyrosine kinase—FRS2—nasal cavity cancer	0.0379	0.0379	CbGpPWpGaD
Vandetanib—MKNK1—Negative regulation of FGFR signaling—FRS2—nasal cavity cancer	0.0331	0.0331	CbGpPWpGaD
Vandetanib—TEK—SHP2 signaling—FRS2—nasal cavity cancer	0.0246	0.0246	CbGpPWpGaD
Vandetanib—IRAK4—Toll-like Receptor Signaling Pathway—CXCL11—nasal cavity cancer	0.0197	0.0197	CbGpPWpGaD
Vandetanib—VEGFA—Allograft Rejection—CXCL11—nasal cavity cancer	0.0175	0.0175	CbGpPWpGaD
Vandetanib—SRC—CXCR3-mediated signaling events—CXCL11—nasal cavity cancer	0.0165	0.0165	CbGpPWpGaD
Vandetanib—IRAK4—Regulation of toll-like receptor signaling pathway—CXCL11—nasal cavity cancer	0.0154	0.0154	CbGpPWpGaD
Vandetanib—KDR—SHP2 signaling—FRS2—nasal cavity cancer	0.0147	0.0147	CbGpPWpGaD
Vandetanib—VEGFA—SHP2 signaling—FRS2—nasal cavity cancer	0.0132	0.0132	CbGpPWpGaD
Vandetanib—MKNK1—Signaling by FGFR—FRS2—nasal cavity cancer	0.0108	0.0108	CbGpPWpGaD
Vandetanib—ERBB3—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.0106	0.0106	CbGpPWpGaD
Vandetanib—MKNK1—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Vandetanib—PDGFRB—SHP2 signaling—FRS2—nasal cavity cancer	0.00974	0.00974	CbGpPWpGaD
Vandetanib—ERBB3—PI-3K cascade—FRS2—nasal cavity cancer	0.00958	0.00958	CbGpPWpGaD
Vandetanib—SRC—Signaling events regulated by Ret tyrosine kinase—FRS2—nasal cavity cancer	0.00951	0.00951	CbGpPWpGaD
Vandetanib—ERBB3—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00935	0.00935	CbGpPWpGaD
Vandetanib—SRC—Negative regulation of FGFR signaling—FRS2—nasal cavity cancer	0.00932	0.00932	CbGpPWpGaD
Vandetanib—ERBB3—GAB1 signalosome—FRS2—nasal cavity cancer	0.00928	0.00928	CbGpPWpGaD
Vandetanib—ABL1—Neurotrophic factor-mediated Trk receptor signaling—FRS2—nasal cavity cancer	0.00912	0.00912	CbGpPWpGaD
Vandetanib—ERBB3—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00906	0.00906	CbGpPWpGaD
Vandetanib—SRC—Signalling to ERKs—FRS2—nasal cavity cancer	0.00863	0.00863	CbGpPWpGaD
Vandetanib—EGFR—SHP2 signaling—FRS2—nasal cavity cancer	0.00811	0.00811	CbGpPWpGaD
Vandetanib—LCK—SHP2 signaling—FRS2—nasal cavity cancer	0.00782	0.00782	CbGpPWpGaD
Vandetanib—SRC—FGF signaling pathway—FRS2—nasal cavity cancer	0.00733	0.00733	CbGpPWpGaD
Vandetanib—MAP2K5—BDNF signaling pathway—FRS2—nasal cavity cancer	0.0073	0.0073	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00716	0.00716	CbGpPWpGaD
Vandetanib—PDGFRB—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00711	0.00711	CbGpPWpGaD
Vandetanib—FYN—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00685	0.00685	CbGpPWpGaD
Vandetanib—ERBB3—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00685	0.00685	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00674	0.00674	CbGpPWpGaD
Vandetanib—ERBB3—Downstream signal transduction—FRS2—nasal cavity cancer	0.00644	0.00644	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by FGFR—FRS2—nasal cavity cancer	0.00641	0.00641	CbGpPWpGaD
Vandetanib—PDGFRB—PI-3K cascade—FRS2—nasal cavity cancer	0.0064	0.0064	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00638	0.00638	CbGpPWpGaD
Vandetanib—ERBB3—DAP12 signaling—FRS2—nasal cavity cancer	0.00634	0.00634	CbGpPWpGaD
Vandetanib—YES1—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00628	0.00628	CbGpPWpGaD
Vandetanib—ERBB3—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00625	0.00625	CbGpPWpGaD
Vandetanib—PDGFRB—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00625	0.00625	CbGpPWpGaD
Vandetanib—PDGFRB—GAB1 signalosome—FRS2—nasal cavity cancer	0.0062	0.0062	CbGpPWpGaD
Vandetanib—FYN—PI-3K cascade—FRS2—nasal cavity cancer	0.00617	0.00617	CbGpPWpGaD
Vandetanib—PDGFRB—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00606	0.00606	CbGpPWpGaD
Vandetanib—BLK—B Cell Activation—FRS2—nasal cavity cancer	0.00603	0.00603	CbGpPWpGaD
Vandetanib—FYN—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00603	0.00603	CbGpPWpGaD
Vandetanib—FYN—GAB1 signalosome—FRS2—nasal cavity cancer	0.00598	0.00598	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00597	0.00597	CbGpPWpGaD
Vandetanib—ERBB3—DAP12 interactions—FRS2—nasal cavity cancer	0.00597	0.00597	CbGpPWpGaD
Vandetanib—ERBB3—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00597	0.00597	CbGpPWpGaD
Vandetanib—LYN—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00593	0.00593	CbGpPWpGaD
Vandetanib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00592	0.00592	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by EGFR—FRS2—nasal cavity cancer	0.00592	0.00592	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00586	0.00586	CbGpPWpGaD
Vandetanib—FYN—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00584	0.00584	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by PDGF—FRS2—nasal cavity cancer	0.00584	0.00584	CbGpPWpGaD
Vandetanib—LCK—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.0057	0.0057	CbGpPWpGaD
Vandetanib—YES1—Signaling by ERBB2—FRS2—nasal cavity cancer	0.0056	0.0056	CbGpPWpGaD
Vandetanib—ERBB3—B Cell Activation—FRS2—nasal cavity cancer	0.00552	0.00552	CbGpPWpGaD
Vandetanib—MAP2K5—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00548	0.00548	CbGpPWpGaD
Vandetanib—EGFR—PI-3K cascade—FRS2—nasal cavity cancer	0.00533	0.00533	CbGpPWpGaD
Vandetanib—ERBB3—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00529	0.00529	CbGpPWpGaD
Vandetanib—EGFR—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00521	0.00521	CbGpPWpGaD
Vandetanib—EGFR—GAB1 signalosome—FRS2—nasal cavity cancer	0.00516	0.00516	CbGpPWpGaD
Vandetanib—LCK—PI-3K cascade—FRS2—nasal cavity cancer	0.00514	0.00514	CbGpPWpGaD
Vandetanib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00505	0.00505	CbGpPWpGaD
Vandetanib—LCK—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00502	0.00502	CbGpPWpGaD
Vandetanib—LCK—GAB1 signalosome—FRS2—nasal cavity cancer	0.00498	0.00498	CbGpPWpGaD
Vandetanib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00486	0.00486	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00479	0.00479	CbGpPWpGaD
Vandetanib—LYN—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00469	0.00469	CbGpPWpGaD
Vandetanib—FYN—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00461	0.00461	CbGpPWpGaD
Vandetanib—RIPK2—Signaling by NGF—FRS2—nasal cavity cancer	0.00461	0.00461	CbGpPWpGaD
Vandetanib—PDGFRB—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00458	0.00458	CbGpPWpGaD
Vandetanib—FYN—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00454	0.00454	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00451	0.00451	CbGpPWpGaD
Vandetanib—FYN—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00441	0.00441	CbGpPWpGaD
Vandetanib—SRC—GAB1 signalosome—FRS2—nasal cavity cancer	0.00441	0.00441	CbGpPWpGaD
Vandetanib—FYN—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00434	0.00434	CbGpPWpGaD
Vandetanib—PDGFRB—Downstream signal transduction—FRS2—nasal cavity cancer	0.0043	0.0043	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by FGFR—FRS2—nasal cavity cancer	0.00428	0.00428	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00426	0.00426	CbGpPWpGaD
Vandetanib—PDGFRB—DAP12 signaling—FRS2—nasal cavity cancer	0.00424	0.00424	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling by NGF—FRS2—nasal cavity cancer	0.00422	0.00422	CbGpPWpGaD
Vandetanib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00418	0.00418	CbGpPWpGaD
Vandetanib—FYN—Downstream signal transduction—FRS2—nasal cavity cancer	0.00415	0.00415	CbGpPWpGaD
Vandetanib—FYN—Signaling by FGFR—FRS2—nasal cavity cancer	0.00413	0.00413	CbGpPWpGaD
Vandetanib—FYN—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00411	0.00411	CbGpPWpGaD
Vandetanib—FYN—DAP12 signaling—FRS2—nasal cavity cancer	0.00409	0.00409	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by NGF—FRS2—nasal cavity cancer	0.00407	0.00407	CbGpPWpGaD
Vandetanib—FYN—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00403	0.00403	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00399	0.00399	CbGpPWpGaD
Vandetanib—PDGFRB—DAP12 interactions—FRS2—nasal cavity cancer	0.00399	0.00399	CbGpPWpGaD
Vandetanib—PDGFRB—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00399	0.00399	CbGpPWpGaD
Vandetanib—EGFR—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00399	0.00399	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by EGFR—FRS2—nasal cavity cancer	0.00395	0.00395	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00392	0.00392	CbGpPWpGaD
Vandetanib—LYN—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00391	0.00391	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by PDGF—FRS2—nasal cavity cancer	0.0039	0.0039	CbGpPWpGaD
Vandetanib—FYN—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00385	0.00385	CbGpPWpGaD
Vandetanib—FYN—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00385	0.00385	CbGpPWpGaD
Vandetanib—FYN—DAP12 interactions—FRS2—nasal cavity cancer	0.00385	0.00385	CbGpPWpGaD
Vandetanib—LCK—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00384	0.00384	CbGpPWpGaD
Vandetanib—EGFR—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00381	0.00381	CbGpPWpGaD
Vandetanib—FYN—Signaling by EGFR—FRS2—nasal cavity cancer	0.00381	0.00381	CbGpPWpGaD
Vandetanib—FYN—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00378	0.00378	CbGpPWpGaD
Vandetanib—FYN—Signaling by PDGF—FRS2—nasal cavity cancer	0.00376	0.00376	CbGpPWpGaD
Vandetanib—EGFR—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00375	0.00375	CbGpPWpGaD
Vandetanib—PDGFRB—B Cell Activation—FRS2—nasal cavity cancer	0.00369	0.00369	CbGpPWpGaD
Vandetanib—LCK—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00368	0.00368	CbGpPWpGaD
Vandetanib—LCK—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00362	0.00362	CbGpPWpGaD
Vandetanib—LYN—B Cell Activation—FRS2—nasal cavity cancer	0.00362	0.00362	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—CXCL11—nasal cavity cancer	0.00361	0.00361	CbGpPWpGaD
Vandetanib—EGFR—Downstream signal transduction—FRS2—nasal cavity cancer	0.00358	0.00358	CbGpPWpGaD
Vandetanib—EGFR—Signaling by FGFR—FRS2—nasal cavity cancer	0.00357	0.00357	CbGpPWpGaD
Vandetanib—FYN—B Cell Activation—FRS2—nasal cavity cancer	0.00356	0.00356	CbGpPWpGaD
Vandetanib—EGFR—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00355	0.00355	CbGpPWpGaD
Vandetanib—PDGFRB—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00353	0.00353	CbGpPWpGaD
Vandetanib—EGFR—DAP12 signaling—FRS2—nasal cavity cancer	0.00353	0.00353	CbGpPWpGaD
Vandetanib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00348	0.00348	CbGpPWpGaD
Vandetanib—LCK—Downstream signal transduction—FRS2—nasal cavity cancer	0.00345	0.00345	CbGpPWpGaD
Vandetanib—LCK—Signaling by FGFR—FRS2—nasal cavity cancer	0.00344	0.00344	CbGpPWpGaD
Vandetanib—LCK—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00342	0.00342	CbGpPWpGaD
Vandetanib—FYN—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00341	0.00341	CbGpPWpGaD
Vandetanib—LCK—DAP12 signaling—FRS2—nasal cavity cancer	0.0034	0.0034	CbGpPWpGaD
Vandetanib—SRC—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.0034	0.0034	CbGpPWpGaD
Vandetanib—LCK—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00335	0.00335	CbGpPWpGaD
Vandetanib—SRC—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00334	0.00334	CbGpPWpGaD
Vandetanib—EGFR—DAP12 interactions—FRS2—nasal cavity cancer	0.00332	0.00332	CbGpPWpGaD
Vandetanib—EGFR—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00332	0.00332	CbGpPWpGaD
Vandetanib—EGFR—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00332	0.00332	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—CXCL11—nasal cavity cancer	0.0033	0.0033	CbGpPWpGaD
Vandetanib—EGFR—Signaling by EGFR—FRS2—nasal cavity cancer	0.00329	0.00329	CbGpPWpGaD
Vandetanib—EGFR—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00326	0.00326	CbGpPWpGaD
Vandetanib—EGFR—Signaling by PDGF—FRS2—nasal cavity cancer	0.00325	0.00325	CbGpPWpGaD
Vandetanib—LCK—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0032	0.0032	CbGpPWpGaD
Vandetanib—LCK—DAP12 interactions—FRS2—nasal cavity cancer	0.0032	0.0032	CbGpPWpGaD
Vandetanib—LCK—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0032	0.0032	CbGpPWpGaD
Vandetanib—LCK—Signaling by EGFR—FRS2—nasal cavity cancer	0.00317	0.00317	CbGpPWpGaD
Vandetanib—LCK—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00315	0.00315	CbGpPWpGaD
Vandetanib—LCK—Signaling by PDGF—FRS2—nasal cavity cancer	0.00313	0.00313	CbGpPWpGaD
Vandetanib—EGFR—B Cell Activation—FRS2—nasal cavity cancer	0.00308	0.00308	CbGpPWpGaD
Vandetanib—SRC—Downstream signal transduction—FRS2—nasal cavity cancer	0.00306	0.00306	CbGpPWpGaD
Vandetanib—SRC—Signaling by FGFR—FRS2—nasal cavity cancer	0.00304	0.00304	CbGpPWpGaD
Vandetanib—SRC—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00303	0.00303	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00302	0.00302	CbGpPWpGaD
Vandetanib—LCK—B Cell Activation—FRS2—nasal cavity cancer	0.00296	0.00296	CbGpPWpGaD
Vandetanib—EGFR—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00294	0.00294	CbGpPWpGaD
Vandetanib—IRAK4—Innate Immune System—FRS2—nasal cavity cancer	0.00291	0.00291	CbGpPWpGaD
Vandetanib—LCK—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00284	0.00284	CbGpPWpGaD
Vandetanib—SRC—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00283	0.00283	CbGpPWpGaD
Vandetanib—SRC—Signaling by EGFR—FRS2—nasal cavity cancer	0.00281	0.00281	CbGpPWpGaD
Vandetanib—SRC—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00278	0.00278	CbGpPWpGaD
Vandetanib—SRC—Signaling by PDGF—FRS2—nasal cavity cancer	0.00277	0.00277	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by NGF—FRS2—nasal cavity cancer	0.00272	0.00272	CbGpPWpGaD
Vandetanib—RIPK2—Innate Immune System—FRS2—nasal cavity cancer	0.00263	0.00263	CbGpPWpGaD
Vandetanib—FYN—Signaling by NGF—FRS2—nasal cavity cancer	0.00262	0.00262	CbGpPWpGaD
Vandetanib—RIPK2—Adaptive Immune System—FRS2—nasal cavity cancer	0.00253	0.00253	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—FRS2—nasal cavity cancer	0.00252	0.00252	CbGpPWpGaD
Vandetanib—SRC—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00251	0.00251	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.0025	0.0025	CbGpPWpGaD
Vandetanib—BLK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00243	0.00243	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—FRS2—nasal cavity cancer	0.00232	0.00232	CbGpPWpGaD
Vandetanib—EGFR—Signaling by NGF—FRS2—nasal cavity cancer	0.00226	0.00226	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—FRS2—nasal cavity cancer	0.00223	0.00223	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—FRS2—nasal cavity cancer	0.00218	0.00218	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—FRS2—nasal cavity cancer	0.00213	0.00213	CbGpPWpGaD
Vandetanib—MKNK1—Disease—FRS2—nasal cavity cancer	0.0021	0.0021	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—FRS2—nasal cavity cancer	0.00204	0.00204	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—FRS2—nasal cavity cancer	0.00195	0.00195	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—FRS2—nasal cavity cancer	0.00194	0.00194	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—FRS2—nasal cavity cancer	0.00193	0.00193	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—FRS2—nasal cavity cancer	0.00178	0.00178	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—FRS2—nasal cavity cancer	0.00169	0.00169	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00168	0.00168	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—FRS2—nasal cavity cancer	0.00155	0.00155	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CXCL11—nasal cavity cancer	0.00154	0.00154	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—FRS2—nasal cavity cancer	0.00153	0.00153	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—FRS2—nasal cavity cancer	0.00152	0.00152	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—FRS2—nasal cavity cancer	0.00151	0.00151	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CXCL11—nasal cavity cancer	0.0015	0.0015	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—FRS2—nasal cavity cancer	0.00149	0.00149	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—FRS2—nasal cavity cancer	0.00149	0.00149	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00148	0.00148	CbGpPWpGaD
Vandetanib—BLK—Immune System—FRS2—nasal cavity cancer	0.00147	0.00147	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—FRS2—nasal cavity cancer	0.00147	0.00147	CbGpPWpGaD
Vandetanib—FGR—Immune System—FRS2—nasal cavity cancer	0.00147	0.00147	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—FRS2—nasal cavity cancer	0.00146	0.00146	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—FRS2—nasal cavity cancer	0.00144	0.00144	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0014	0.0014	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—FRS2—nasal cavity cancer	0.00135	0.00135	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CXCL11—nasal cavity cancer	0.00135	0.00135	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CXCL11—nasal cavity cancer	0.0013	0.0013	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—FRS2—nasal cavity cancer	0.00129	0.00129	CbGpPWpGaD
Vandetanib—ERBB3—Disease—FRS2—nasal cavity cancer	0.00125	0.00125	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—FRS2—nasal cavity cancer	0.00124	0.00124	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—FRS2—nasal cavity cancer	0.00124	0.00124	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00119	0.00119	CbGpPWpGaD
Vandetanib—YES1—Immune System—FRS2—nasal cavity cancer	0.00119	0.00119	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—FRS2—nasal cavity cancer	0.0011	0.0011	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—FRS2—nasal cavity cancer	0.00106	0.00106	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCL11—nasal cavity cancer	0.000991	0.000991	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—FRS2—nasal cavity cancer	0.000991	0.000991	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCL11—nasal cavity cancer	0.00097	0.00097	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL11—nasal cavity cancer	0.000955	0.000955	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—FRS2—nasal cavity cancer	0.000906	0.000906	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—FRS2—nasal cavity cancer	0.000903	0.000903	CbGpPWpGaD
Vandetanib—LYN—Immune System—FRS2—nasal cavity cancer	0.000884	0.000884	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—FRS2—nasal cavity cancer	0.000883	0.000883	CbGpPWpGaD
Vandetanib—ABL1—Immune System—FRS2—nasal cavity cancer	0.00088	0.00088	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—FRS2—nasal cavity cancer	0.000873	0.000873	CbGpPWpGaD
Vandetanib—FYN—Immune System—FRS2—nasal cavity cancer	0.00087	0.00087	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—FRS2—nasal cavity cancer	0.000834	0.000834	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL11—nasal cavity cancer	0.000825	0.000825	CbGpPWpGaD
Vandetanib—FYN—Disease—FRS2—nasal cavity cancer	0.000804	0.000804	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL11—nasal cavity cancer	0.000795	0.000795	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—FRS2—nasal cavity cancer	0.000794	0.000794	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—FRS2—nasal cavity cancer	0.000767	0.000767	CbGpPWpGaD
Vandetanib—EGFR—Immune System—FRS2—nasal cavity cancer	0.000752	0.000752	CbGpPWpGaD
Vandetanib—ABCC1—Disease—FRS2—nasal cavity cancer	0.000737	0.000737	CbGpPWpGaD
Vandetanib—LCK—Immune System—FRS2—nasal cavity cancer	0.000725	0.000725	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL11—nasal cavity cancer	0.000704	0.000704	CbGpPWpGaD
Vandetanib—EGFR—Disease—FRS2—nasal cavity cancer	0.000694	0.000694	CbGpPWpGaD
Vandetanib—LCK—Disease—FRS2—nasal cavity cancer	0.000669	0.000669	CbGpPWpGaD
Vandetanib—SRC—Immune System—FRS2—nasal cavity cancer	0.000642	0.000642	CbGpPWpGaD
Vandetanib—SRC—Disease—FRS2—nasal cavity cancer	0.000592	0.000592	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FRS2—nasal cavity cancer	0.000584	0.000584	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FRS2—nasal cavity cancer	0.000572	0.000572	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FRS2—nasal cavity cancer	0.000563	0.000563	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FRS2—nasal cavity cancer	0.000486	0.000486	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FRS2—nasal cavity cancer	0.000469	0.000469	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FRS2—nasal cavity cancer	0.000415	0.000415	CbGpPWpGaD
